Sanofi-Aventis said on April 3rd it still has high hopes for diet drug rimonabant (Acomplia / Zimulti), even though it was rejected by a U.S. FDA advisory panel last year and recent clinical trial news has been less than wildly …
The drug, rimonabant, which the French company Sanofi-Aventis hopes to sell under the brand name Acomplia, trimmed nearly 16 pounds on average from people taking the optimal dose for two years, compared with 5.5 pounds for those who took dummy …
Rimonabant Acomplia Helps With Weight Loss
Rimonabant Acomplia is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is …